Our Under Development Product

Clindamycin for Dogs & Cats First-Line Antibiotic for Skin & Soft Tissue Infections
Clinical Indications

Skin and soft tissue infections caused by susceptible bacteria

Oral cavity and periodontal infections

Bone and joint infections including osteomyelitis

Infections caused by Staphylococcus, Streptococcus, Bacteroides, and anaerobic pathogens

Target Dosage Form

Palatable Suspension – Priority formulation for SEA market in 30 mL bottles. Tablet compliance is notoriously poor, especially in cats and small dogs, creating strong demand for taste-masked, heat-stable suspension formulations.

SEA Market Rationale

Clindamycin represents a critical gap in the Southeast Asian market. While widely used globally, locally available options are limited to poorly compliant tablet formats. The tropical climate demands suspension formulations with superior stability profiles.

Manufacturing Discussion Points

Cost optimization strategies for accessible pricing

Taste-masking capability and palatability optimization

Suspension stability under high heat and humidity conditions

Multi-strength formulation flexibility (targeting both cats and dogs)

Clindamycin: Dosing & Administration

Dogs

Infected Wounds, Abscesses & Dental Infections

Dose: 5.5 mg/kg body weight every 12 hours

Duration: Treatment may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Canine Osteomyelitis

Dose: 11 mg/kg body weight every 12 hours

Duration: Treatment is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

Cats

Infected Wounds, Abscesses & Dental Infections

Dose: 11-22 mg/kg body weight once every 24 hours, depending on severity

To provide 11 mg/kg: administer 0.5 mL/kg body weight once daily and To provide 22 mg/kg: administer 1 mL/kg body weight once daily

Duration: Treatment may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Specific Pathogens: Effective against Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens, and Bacteroides fragilis.

Doxycycline Monohydrate – Superior GI Tolerance Second-Generation Tetracycline for Dogs & Cats Clinical Indications Tick-borne diseases (Ehrlichia, Anaplasma, Rickettsia)
Respiratory tract infections
Chlamydophila and Mycoplasma infections
Leptospirosis treatment and prevention
Urinary tract infections
Amoxicillin-Clavulanic Acid Product Line Broad-spectrum first-line antibiotic representing the cornerstone of companion animal practice. This staple product addresses the highest-volume antibiotic needs in veterinary medicine with predictable demand and proven clinical efficacy.
General Line Extension Standard ratios for skin, respiratory, urinary tract, and oral infections. High-volume demand with competitive pricing advantages through local Thai manufacturing.
Dermatological Core (4:1 Ratio) Clavamox-type formulation specifically optimized for dermatology cases. First-line dermatological antibiotic designed for tropical climate stability.Dermatological Core (4:1 Ratio)
Dermatological Core Strength Portfolio
Total StrengthAmoxicillinClavulanic AcidTarget Species
62.5 mg50 mg12.5 mgDogs & Cats
125 mg100 mg25 mgDogs
250 mg200 mg50 mgDogs
500 mg400 mg100 mgDogs
Dermatological Solutions for Tropical Climates

Why Dermatology Focus?

Dermatological cases represent the single most common clinical presentation in Southeast Asian companion animal practice. The combination of year-round heat, high humidity, and specific regional allergens creates an environment where skin conditions flourish.

Current treatment options are either prohibitively expensive imported products or generic alternatives with questionable stability under tropical conditions. This creates a substantial opportunity for locally manufactured, climate-optimized dermatology solutions.

Manufacturing Considerations Clavulanic Acid Stability: The most challenging component requiring careful formulation and packaging to maintain potency in hot, humid environments
Tablet Hardness Balance: Must be hard enough for stability yet maintain reasonable palatability for direct administration
Scored Tablet Feasibility: Enable accurate dosing across different weight ranges without compromising tablet integrity
Shelf Life Under ASEAN Conditions: Target minimum 18-24 months under accelerated stability protocols representing real-world tropical storage